Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter Completed Phase 2 Trials for Trastuzumab (DB00072)

Also known as: Transitional cell cancer of the renal pelvis and ureter recurrent / Renal pelvis and ureter transitional cell cancer recurrent / Renal pelvis and ureteric cancer recurrent transitional cell / Renal pelvis and ureteral cancer transitional cell recurrent / Renal pelvis and ureteric cancer transitional cell recurrent

IndicationStatusPhase
DBCOND0028816 (Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00005831Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract CancerTreatment